 previous article in this issue | next article in this issue  |
|
Document Details : Title: Donepezil-related toxic hepatitis Author(s): DIERCKX RIR, VANDEWOUDE MFJ Journal: Acta Clinica Belgica Volume: 63 Issue: 5 Date: 2008 Pages: 339-342 DOI: 10.2143/ACB.63.5.1002590 Abstract : Alzheimer’s disease (AD) is the leading cause of dementia. It is characterized by the presence of senile plaques and neurofibrillary tangles in the brain, and impairment of the central cholinergic system, which contribute to memory loss and cognitive dysfunction. Cholinesterase inhibitors prevent the hydrolysis of acetylcholine and are currently approved for the symptomatic treatment of Alzheimer’s disease. Donepezil, a piperidinebased, reversible and specific inhibitor of acetylcholinesterase, has been demonstrated to be clinically effective in the treatment of patients with mild to moderate AD. To date, clinical trials have not reported an association between treatment with donepezil and hepatotoxicity. We describe a case of toxic hepatitis, documented by liver biopsy, in a patient treated with donepezil. |
